Poly(ADP-ribose) polymerase inhibitors as cancer therapy.

  title={Poly(ADP-ribose) polymerase inhibitors as cancer therapy.},
  author={John Frederick Hilton and Matthew J Hadfield and Minh-Thu Tran and Geoffrey I. Shapiro},
  journal={Frontiers in bioscience},
Poly(ADP-ribose) polymerase (PARP) inhibitors are pharmacologic agents which primarily inhibit the PARP-1 and PARP-2 enzymes within the cell. Inhibition of PARP results in failure of base-excision repair (BER) to correct single-stranded breaks in DNA. This failure results in double-stranded breaks that are subsequently repaired either by homologous recombination (HR) repair, which is error-free, or by non-homologous end joining (NHEJ), which is an error-prone process. Clinically, PARP… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS